- Home
- TLSI vs FINW Comparison
TLSI vs FINW Comparison
Compare TLSI & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLSI | FINW |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 245.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TLSI | FINW |
|---|---|---|
| Price | $7.08 | $17.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $11.50 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 210.1K | 22.5K |
| Earning Date | 11-13-2025 | 01-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.05 |
| Revenue | $40,207,000.00 | ★ $80,198,000.00 |
| Revenue This Year | $55.06 | $83.64 |
| Revenue Next Year | $46.04 | $38.08 |
| P/E Ratio | ★ N/A | $17.06 |
| Revenue Growth | ★ 49.52 | 14.76 |
| 52 Week Low | $3.42 | $13.49 |
| 52 Week High | $7.95 | $22.49 |
Technical Indicators
Market Signals| Indicator | TLSI | FINW |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 45.66 |
| Support Level | $6.61 | $17.57 |
| Resistance Level | $7.95 | $18.16 |
| Average True Range (ATR) | 0.43 | 0.53 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 24.63 | 41.99 |
Price Performance
Historical ComparisonAbout TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.